Fractyl Health, Inc. (Nasdaq: GUTS) announced its financial results for the fourth quarter and full year ended December 31, 2025, alongside significant updates regarding its clinical programs. The company reported a net loss of $43.7 million for the quarter, an increase from $25.0 million in the same period last year, primarily due to a non-cash accounting change related to warrant liabilities. Research and development expenses decreased to $16.5 million from $20.3 million, reflecting strategic reprioritization efforts. Fractyl also highlighted the completion of randomization in its REMAIN-1 Pivotal Cohort, with topline data expected in early Q4 2026. The company received favorable FDA feedback on its De Novo classification request, with a submission anticipated in late Q4 2026. Notably, new post-hoc analyses from the REMAIN-1 Midpoint Cohort demonstrated a statistically significant correlation between treatment effect and ablation length, reinforcing the potential of Revita as a procedural option for weight maintenance following GLP-1 therapy discontinuation. Fractyl reiterated its cash runway guidance into early 2027, beyond the pivotal data readout, indicating a strong financial position to support ongoing operations and clinical trials.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.